❌

Normal view

Supervised Reinforcement Learning: From Expert Trajectories to Step-wise Reasoning

arXiv:2510.25992v1 Announce Type: cross Abstract: Large Language Models (LLMs) often struggle with problems that require multi-step reasoning. For small-scale open-source models, Reinforcement Learning with Verifiable Rewards (RLVR) fails when correct solutions are rarely sampled even after many attempts, while Supervised Fine-Tuning (SFT) tends to overfit long demonstrations through rigid token-by-token imitation. To address this gap, we propose Supervised Reinforcement Learning (SRL), a framework that reformulates problem solving as generating a sequence of logical "actions". SRL trains the model to generate an internal reasoning monologue before committing to each action. It provides smoother rewards based on the similarity between the model's actions and expert actions extracted from the SFT dataset in a step-wise manner. This supervision offers richer learning signals even when all rollouts are incorrect, while encouraging flexible reasoning guided by expert demonstrations. As a result, SRL enables small models to learn challenging problems previously unlearnable by SFT or RLVR. Moreover, initializing training with SRL before refining with RLVR yields the strongest overall performance. Beyond reasoning benchmarks, SRL generalizes effectively to agentic software engineering tasks, establishing it as a robust and versatile training framework for reasoning-oriented LLMs.

Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy

24 October 2025 at 18:00

Transl Lung Cancer Res. 2025 Sep 30;14(9):4112-4130. doi: 10.21037/tlcr-2025-350. Epub 2025 Sep 18.

ABSTRACT

Lung squamous cell carcinoma (LUSC), a predominant type of lung cancer, is marked by an unfavorable prognosis and limited therapeutic options. Unlike lung adenocarcinoma (LUAD), LUSC exhibits few driver mutations, resulting in minimal benefits from targeted therapies for these patients. Despite the transformative effects of immunotherapy on patient outcomes, only a subset of patients achieving durable responses. This heterogeneity in treatment outcomes is increasingly attributed to the complex feature of the tumor immune microenvironment (TIME) in LUSC. The TIME of LUSC is a highly dynamic ecosystem composed of diverse immune cell populations and stromal components that collectively foster an immune-evasive niche. Recent breakthroughs in multi-omics technologies, particularly single-cell RNA sequencing (scRNA-seq) and spatial omics, have provided unprecedented resolution in dissecting the cellular and molecular architecture of the TIME in LUSC. These technologies have enabled the identification of distinct immune cells and their spatial interactions with the tumor, shedding light on the mechanisms underlying immune evasion and resistance to immunotherapy. Building on these advancements, this review establishes a new classification of the TIME which may guide patient stratification and personalized immunotherapy. And we comprehensively offer a detailed examination of the principal characteristics and regulatory mechanisms of the TIME, highlighting potential immunotherapeutic strategies tailored to this distinct immunological context.

PMID:41133013 | PMC:PMC12541881 | DOI:10.21037/tlcr-2025-350

Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review

Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00178-6. doi: 10.1016/j.euf.2025.06.009. Online ahead of print.

ABSTRACT

BACKGROUND AND OBJECTIVE: Urinary tumor DNA (utDNA) has emerged as a promising biomarker in the care, diagnosis, early detection, recurrence monitoring, and prognosis of bladder cancer (BCa). Its noninvasive nature, ease of access, and cost effectiveness make it an attractive option for both patients and health care providers. This review describes the current state of utDNA as a marker of BCa.

METHODS: Articles published between 2015 and 2025 on current utDNA-based techniques in BCa were identified and analyzed for relevance and insight into utDNA research and usage.

KEY FINDINGS AND LIMITATIONS: Recent investigations underscore the noninvasiveness and superior tumor detection capabilities of utDNA, particularly in the detection of minimal residual disease. Moreover, utDNA provides actionable information, such as tumor grade and staging information, to support precise treatment decisions, including targeted immunotherapy regimens and bladder preservation strategies. Although utDNA has shown promising results in small studies, larger studies must be performed before it can be considered as a standard procedure in clinical practice.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Urinary tumor DNA has demonstrated great potential to improve on most, if not all, stages of detection, treatment, and monitoring of BCa. By preserving the low cost and noninvasiveness of urine cytology, and by replacing its suboptimal accuracy with a precision rivaling and often exceeding cystoscopy and circulating tumor DNA-based methods, utDNA offers patients a more comfortable, repeatable, and accurate way of detecting BCa. With increased sensitivity and accuracy, everything from low-grade tumors to the earliest signs of recurrence can be detected more effectively, optimizing patient treatment courses and improving outcomes.

PMID:40753029 | DOI:10.1016/j.euf.2025.06.009

❌